Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Texas77 who wrote (1021)	8/11/1998 3:59:00 PM
From: jake burns	Read Replies (1) \| Respond to of 1510

I'm not sure. I would say YES if I knew for sure that the company would file an application in October with the FDA for REMUNE's approval in combination with the antivirals. Absent that, we could be in a funk for a while. The psoriasis results are due in September. Dr. Valentine presents in late september. Supposedly, analysts could come on board....if you like the company, invest today because it's a more than fair price.

To: Texas77 who wrote (1021)	8/11/1998 6:03:00 PM
From: John S. Baker	Read Replies (1) \| Respond to of 1510

I agree with Jake that today's price is a pretty fair one. And his point ... posted here before ... that IMNR is not a single-product company; rather it has a number of projects in the fire, which results in multiple opportunities for real news even before the FDA approval of Remune. I already have all the IMNR that my "balanced investment portfolio" can handle, but I am always happy to gobble up a few more shares for trading purposes. FWIW, my TA sez I am on the verge of doing so ... but not today or tomorrow. Will advise. JSb.